CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
Abstract CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute ly...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2007 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576186741424128 |
|---|---|
| author | Lucas Touzet Florent Dumezy Christophe Roumier Céline Berthon Claire Bories Bruno Quesnel Claude Preudhomme Thomas Boyer |
| author_facet | Lucas Touzet Florent Dumezy Christophe Roumier Céline Berthon Claire Bories Bruno Quesnel Claude Preudhomme Thomas Boyer |
| author_sort | Lucas Touzet |
| collection | DOAJ |
| description | Abstract CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute lymphoblastic leukemia (ALL), this marker has not yet been studied in acute myeloid leukemia (AML). First, we explored its prognostic role and its association with biological factors in a cohort of 112 AML patients treated with intensive chemotherapy. CD9 was expressed in 40% of AML and was associated with a favorable outcome (event‐free survival and relapse‐free survival) in univariate (P = 0.009 and P = 0.048, respectively) and multivariate (P = 0.004 and P = 0.039, respectively) analyses. Interestingly, CD9 expression was different between the more immature physiologic and AML cells (CD34+CD38−) as it was also expressed in AML on putative leukemic stem cells (LSCs) but not on hematopoietic stem cells (HSCs). Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting. |
| format | Article |
| id | doaj-art-2625930667cd4d70b67bc83b98497fad |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-2625930667cd4d70b67bc83b98497fad2025-01-31T08:47:43ZengWileyCancer Medicine2045-76342019-03-01831279128810.1002/cam4.2007CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cellsLucas Touzet0Florent Dumezy1Christophe Roumier2Céline Berthon3Claire Bories4Bruno Quesnel5Claude Preudhomme6Thomas Boyer7Laboratory of Hematology CHU Lille Lille FranceLaboratory of Hematology CHU Lille Lille FranceLaboratory of Hematology CHU Lille Lille FranceDepartment of Hematology CHU Lille Lille FranceDepartment of Hematology CHU Lille Lille FranceDepartment of Hematology CHU Lille Lille FranceLaboratory of Hematology CHU Lille Lille FranceLaboratory of Hematology CHU Lille Lille FranceAbstract CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute lymphoblastic leukemia (ALL), this marker has not yet been studied in acute myeloid leukemia (AML). First, we explored its prognostic role and its association with biological factors in a cohort of 112 AML patients treated with intensive chemotherapy. CD9 was expressed in 40% of AML and was associated with a favorable outcome (event‐free survival and relapse‐free survival) in univariate (P = 0.009 and P = 0.048, respectively) and multivariate (P = 0.004 and P = 0.039, respectively) analyses. Interestingly, CD9 expression was different between the more immature physiologic and AML cells (CD34+CD38−) as it was also expressed in AML on putative leukemic stem cells (LSCs) but not on hematopoietic stem cells (HSCs). Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting.https://doi.org/10.1002/cam4.2007acute myeloid leukemiaAMLCD9leukemia stem cellsLSCminimal residual disease |
| spellingShingle | Lucas Touzet Florent Dumezy Christophe Roumier Céline Berthon Claire Bories Bruno Quesnel Claude Preudhomme Thomas Boyer CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells Cancer Medicine acute myeloid leukemia AML CD9 leukemia stem cells LSC minimal residual disease |
| title | CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells |
| title_full | CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells |
| title_fullStr | CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells |
| title_full_unstemmed | CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells |
| title_short | CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells |
| title_sort | cd9 in acute myeloid leukemia prognostic role and usefulness to target leukemic stem cells |
| topic | acute myeloid leukemia AML CD9 leukemia stem cells LSC minimal residual disease |
| url | https://doi.org/10.1002/cam4.2007 |
| work_keys_str_mv | AT lucastouzet cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT florentdumezy cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT christopheroumier cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT celineberthon cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT clairebories cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT brunoquesnel cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT claudepreudhomme cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells AT thomasboyer cd9inacutemyeloidleukemiaprognosticroleandusefulnesstotargetleukemicstemcells |